Published in Sci Transl Med on February 24, 2010
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Pancreatic cancer. Lancet (2004) 11.63
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res (2011) 6.97
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov (2013) 2.87
Individualized medicine from prewomb to tomb. Cell (2014) 2.76
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol (2011) 2.64
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
The expanding scope of DNA sequencing. Nat Biotechnol (2012) 2.57
Sequencing technologies and genome sequencing. J Appl Genet (2011) 2.52
Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev (2011) 2.31
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med (2013) 2.28
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn (2013) 2.20
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med (2012) 2.13
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biol (2011) 2.11
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med (2012) 2.00
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov (2014) 1.77
Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants. Mutat Res (2011) 1.75
Converting cancer therapies into cures: lessons from infectious diseases. Cell (2012) 1.65
Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol (2011) 1.60
Detecting circulating tumor cells: current challenges and new trends. Theranostics (2013) 1.55
Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52
Cancer genomics identifies determinants of tumor biology. Genome Biol (2010) 1.47
Genetic alterations in colorectal cancer. Gastrointest Cancer Res (2012) 1.44
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
Simultaneous structural variation discovery among multiple paired-end sequenced genomes. Genome Res (2011) 1.39
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med (2015) 1.37
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27
Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med (2011) 1.27
Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol (2014) 1.21
Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer (2014) 1.20
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A (2015) 1.18
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clin Cancer Res (2015) 1.18
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res (2010) 1.17
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J (2011) 1.13
mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One (2012) 1.12
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol (2014) 1.12
Translational implications of tumor heterogeneity. Clin Cancer Res (2015) 1.12
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease. PLoS One (2015) 1.10
Characterization of complex chromosomal rearrangements by targeted capture and next-generation sequencing. Genome Res (2011) 1.10
Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet (2014) 1.09
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience (2014) 1.07
Circulating tumor cells and DNA as liquid biopsies. Genome Med (2013) 1.06
Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol Diagn Ther (2014) 1.02
"Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med (2015) 1.01
Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. BMC Genomics (2011) 1.00
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol (2012) 1.00
The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol (2010) 1.00
Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol (2011) 0.99
The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res (2014) 0.97
Review of massively parallel DNA sequencing technologies. Hugo J (2011) 0.96
Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl Oncol (2013) 0.95
Next-generation sequencing in breast cancer: first take home messages. Curr Opin Oncol (2012) 0.95
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics (2011) 0.94
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics (2014) 0.93
Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia (2014) 0.92
Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med (2015) 0.91
High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. PLoS One (2013) 0.90
Clinical applications of next-generation sequencing in colorectal cancers. World J Gastroenterol (2013) 0.89
Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer (2017) 0.88
Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets (2012) 0.86
Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J Pathol (2013) 0.86
Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol (2014) 0.86
Rapid high-resolution mapping of balanced chromosomal rearrangements on tiling CGH arrays. J Mol Diagn (2011) 0.86
Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. Oncologist (2013) 0.85
Determination of fetal chromosome aberrations from fetal DNA in maternal blood: has the challenge finally been met? Expert Rev Mol Med (2011) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget (2016) 0.85
Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS One (2013) 0.84
Ovarian cancer biomarker discovery based on genomic approaches. J Cancer Prev (2013) 0.84
Blood-based biomarkers for malignant gliomas. J Neurooncol (2013) 0.84
Next generation DNA sequencing and the future of genomic medicine. Genes (Basel) (2010) 0.84
Cancer detection using whole-genome sequencing of cell free DNA. Oncotarget (2013) 0.84
Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch (2016) 0.83
The breast cancer genome--a key for better oncology. BMC Cancer (2011) 0.82
New blood markers detection technology: A leap in the diagnosis of gastric cancer. World J Gastroenterol (2016) 0.82
Tracking tumor resistance using 'liquid biopsies'. Nat Med (2013) 0.82
'Omic approaches to preventing or managing metastatic breast cancer. Breast Cancer Res (2011) 0.81
FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer. Oncotarget (2011) 0.81
Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells. Cancer Res (2013) 0.81
Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalized medicine. PLoS One (2013) 0.81
Prostate cancer epigenetics and its clinical implications. Asian J Androl (2016) 0.80
Epigenetics advancing personalized nanomedicine in cancer therapy. Adv Drug Deliv Rev (2012) 0.80
Molecular classification of breast cancer. Virchows Arch (2014) 0.80
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Paired-end mapping reveals extensive structural variation in the human genome. Science (2007) 30.46
Genetic instabilities in human cancers. Nature (1998) 22.76
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
Accurate multiplex polony sequencing of an evolved bacterial genome. Science (2005) 20.91
Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res (2009) 15.15
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res (2006) 10.45
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer (2007) 9.81
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res (2007) 6.91
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Digital karyotyping. Proc Natl Acad Sci U S A (2002) 3.96
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
BEAMing up for detection and quantification of rare sequence variants. Nat Methods (2006) 3.03
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 1.79
Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther (2006) 1.32
Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. J Clin Oncol (1989) 1.02
Minimal residual disease. Curr Opin Hematol (1999) 1.00
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
International network of cancer genome projects. Nature (2010) 20.35
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res (2009) 15.15
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods (2009) 11.71
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
A high-resolution, nucleosome position map of C. elegans reveals a lack of universal sequence-dictated positioning. Genome Res (2008) 7.77
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
ALLPATHS 2: small genomes assembled accurately and with high continuity from short paired reads. Genome Biol (2009) 6.76
The antisense transcriptomes of human cells. Science (2008) 6.29